Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development.

Zhao MM, Yang WL, Yang FY, Zhang L, Huang WJ, Hou W, Fan CF, Jin RH, Feng YM, Wang YC, Yang JK. · 2021

Read Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. by Zhao MM, Yang WL, Yang FY, Zhang L, Huang WJ, Hou W, Fan CF, Jin RH, Feng YM, Wang YC, Yang JK. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7997800.txt.

Introduction

Zhao and co-authors report a study of cathepsin L, an enzyme that helps SARS-CoV-2 infect human cells. New drug targets were badly needed against COVID-19. The team found the enzyme's level in blood rose after infection. It tracked with how the disease ran and how severe it grew. That hint led them into cells and mice to test its role in entry.

Raising the enzyme in human cells made a test virus enter more easily. Cutting it back did the reverse. The enzyme snips the virus spike, which opens the door for entry. In mice bred with the human doorway protein, the same pattern held. Amantadine, an old flu drug, blocked the enzyme and stopped infection in both settings. The authors name cathepsin L as a promising target for new anti-COVID-19 drugs.

Catalog record

CREATORZhao MM, Yang WL, Yang FY, Zhang L, Huang WJ, Hou W, Fan CF, Jin RH, Feng YM, Wang YC, Yang JK.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE59 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7997800

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development By Miao-Miao Zhao, Wei-Li Yang, Fang-Yuan Yang, Li Zhang, Wei-Jin Huang, Wei Hou, Chang-Fa Fan, Rong-Hua Jin, Ying-Mei Feng, You-Chun Wang, Jin-Kui Yang Published in: Signal Transduction and Targeted Therapy DOI: 10.1038/s41392-021-00558-8 ABSTRACT To discover new drugs to combat COVID-19, an understanding of the molecular basis of SARS-CoV-2 infection is urgently needed. Here, for the first time, we report the crucial role of cathepsin L (CTSL) in patients with COVID-19. The circulating level of CTSL was elevated after SARS-CoV-2 infection and was positively correlated with disease course and severity. Correspondingly, SARS-CoV-2 pseudovirus infection increased CTSL expression in human cells in vitro and human ACE2 transgenic mice in vivo, while CTSL overexpression, in turn, enhanced pseudovirus infection in human cells. CTSL functionally cleaved the SARS-CoV-2 spike protein and enhanced virus entry, as evidenced by CTSL overexpression and knockdown in vitro and application of CTSL inhibitor drugs in vivo. Furthermore, amantadine, a licensed anti-influenza drug, significantly inhibited CTSL activity after SARS-CoV-2 pseudovirus infection and prevented infection both in vitro and in vivo. Therefore, CTSL is a promising target for new anti-COVID-19 drug development. INTRODUCTION The recent outbreak of novel coronavirus (SARS-CoV-2) disease (COVID-19) has imposed a severe public health burden worldwide. To prevent and treat this disease, effective methods, such as vaccines and drugs, are urgently needed. Although vaccination is underway in some countries, the impact of SARS-CoV-2 mutations and the degree of protection that a vaccine could have are some of the main issues under debate.1 On the other hand, the drug is more convenient and acceptable to people. Unfortunately, there is currently no efficient drug that can be used. Thus, the United States Food and Drug Administration (FDA) has approved remdesivir for the treatment of COVID-19 under an emergency use authorization. It is believed that remdesivir may be useful but not universally effective.2 Therefore, broadening the spectrum of therapeutic targets is important. Both SARS-CoV-1, which emerged in 2002, and the novel SARS-CoV-2 infect host cells through binding of their viral envelope spike (S) proteins to the same receptor, angiotensin-converting enzyme 2 (ACE2).3 Our group focused on the correlation between ACE2 and metabolic diseases since the outbreak of SARS-CoV-1 infection in 2003. Our previous study revealed that ACE2 gene is highly associated with diabetes4; loss of ACE2 leads to a decrease in insulin secretion, as well as a progressive impairment of glucose tolerance5,6; ACE2 pathway can ameliorate local blood flow, inflammation, stress state, and fibrosis, which leads to the improvement of glucose transport, lipolysis, and adipokines production.7–9 These findings may partly explain the higher morbidity and mortality in COVID-19 patients combined with diabetes.10 To gain entry into host cells, diverse viruses depend on cleavage and activation of the S protein by host cell proteases.11–14 However, recent studies have focused primarily on furin and transmembrane protease serine 2 (TMPRSS2).3,14 Cathepsin L (CTSL), a member of the lysosomal cysteine protease, contains an L domain of α-helix and an R domain of β-sheet in the spatial structure.15 Its main function is proteolysis of protein antigens produced by pathogen endocytosis.16 Previous studies have indicated that membrane fusion of SARS-CoV-1 relies on proteolysis of the S protein by host CTSL in vitro.17,18 Therefore, it is reasonable to hypothesize that CTSL may be a target for the development of drugs to treat SARS-CoV-2 infection.19,20 This study, for the first time, analyzed circulating levels of CTSL in patients with COVID-19 and systematically studied the therapeutic effects of CTSL on this disease. It indicated that CTSL could be a promising therapeutic target for the prevention and treatment of COVID-19. RESULTS Enrollment and characteristics of patients with COVID-19 A total of 108 consecutive COVID-19 inpatients admitted to Beijing Youan Hospital, Capital Medical University between January 21 and April 30, 2020, were investigated. After excluding 5 patients who were less than 18 years old, 1 pregnant patient, 8 patients who died in a very short time, and 7 patients who were unwilling to participate, 87 patients were ultimately included in the final analysis. Of these 87 patients, 67 had the nonsevere disease (2 mild, 65 moderate) and 20 had severe disease (15 severe, 5 critical) based on the severity classification established by the National Health Committee of China. Detailed demographic and clinical characteristics of the patients with COVID-19 are shown in Supplementary Table 1. The marked increases in aspartate aminotransferase (AST), creatine kinase MB (CK-MB), and myoglobin levels indicated that SARS-CoV-2 attacks liver and cardiac cells, consistent with previous reports.21,22 We also enrolled 125 healthy volunteers who were age- and sex-matched with the COVID-19 patients. Detailed demographic and clinical characteristics of the healthy individuals are shown in Supplementary Table 2. The comparative analysis of the parameters between COVID-19 patients and healthy individuals is shown in Supplementary Table 3. The circulating level of CTSL is elevated in patients with COVID-19 As SARS-CoV-2 shares 79.6% sequence identity with SARS-CoV-1,23 we measured the plasma levels of several proteins that are essential to SARS-CoV-1 entry into host cells. ACE2 is the entry receptor for both SARS-CoV-1 and SARS-CoV-2. The endosomal cysteine proteases CTSL and cathepsin B (CTSB) mediate cleavage of the SARS-CoV-1 S protein, which is necessary for entry of coronavirus into host cells.17,24 Therefore, plasma levels of CTSL, CTSB, ACE2, and its products (angiotensin 1–7 (Ang(1–7)), were measured in patients with COVID-19. Plasma levels of Ang(1–7) were slightly lower in patients with severe disease than in patients with nonsevere disease, while plasma levels of ACE2 were the same between the two groups (Supplementary Table 4). Interestingly, the plasma level of CTSL and CTSL/CTSB were markedly higher, while that of CTSB was slightly lower, in patients with severe disease than in patients with nonsevere disease (Fig. 1a and Supplementary Table 4).Fig. 1Circulating CTSL is elevated in patients with COVID-19. A total of 87 patients with COVID-19, including 20 with severe disease and 67 with nonsevere disease, and 125 healthy volunteers were enrolled in this study. a Plasma CTSL, CTSB, and CTSL/CTSB levels patients with severe (n = 20) and nonsevere COVID-19 (n = 67) upon hospital admission (day 0). Statistical significance was assessed by the Mann–Whitney U test (two-sided). b Plasma CTSL, CTSB and CTSL/CTSB levels in COVID-19 patients (day 0) (n = 87) and age-/sex-matched healthy volunteers (n = 125). The green lines in panels a and b indicate the reference ranges for each parameter, established as the mean values ± 2 SD in the healthy participants. Statistical significance was assessed by the Mann–Whitney U test (two-sided). c Correlation between CTSL in plasma from COVID-19 patients (n = 87) and the number of days from symptom onset to blood collection before therapy. Statistical significance was assessed by Spearman correlation analysis (two-sided). d Flowchart of the follow-up study. Patients were admitted to the hospital on day 0 and experienced a mean hospitalization time of 14 days (day 14). Then, they were followed up on the 14th day (day 28) and the 28th day (day 42) after discharge from the hospital. Blood samples were collected on days 0, 28, and 42. e CTSL levels in plasma from COVID-19 patients (n = 87) on

Read the complete text